Resources & Reports

In early March, the U.S. Food and Drug Administration (FDA) issued 30 warning letters to telehealth companies regarding the illegal marketing of compounded GLP-1 drugs, signaling continued and heightened federal scrutiny of advertising practices. According to the FDA’s March 3, 2026 press release, the agency identified false and misleading claims on telehealth and pharmaceutical company websites related to compounded GLP-1 products, drugs commonly used for weight loss and diabetes management.

As has been reported in previous editions of CCHP’s weekly #TelehealthTuesday emails, including last week’s March newsletter, the Medicare telehealth waivers were extended through December 31, 2027 as a result of the passage of HR 7148 – The Consolidated Appropriations Act, 2026. However, the extension was not the only important telehealth-related item in HR 7148.  The bill also contained several policies that may be new and unfamiliar since they have not previously appeared within existing federal telehealth policy. Below we will highlight four independent items within HR 7148 that readers may want to review.

CCHP’s March newsletter is here! This month’s topics include – VA Rescinds COVID-19 Flexibility for Caregiver Program Home Visits; CMS Launches ACCESS Model to Advance Technology-Supported Chronic Care; Telehealth and Maximum Medical Improvement Determinations in Workers’ Compensation – A 50 State Review; TEFCA Network Hits Milestone with Nearly 500 Million Health Records Exchanged; Key Telehealth Policy Developments from CCHP’s Policy Finder; ICYMI:  FQHC Telehealth Policy Resource & NACHC Summary Factsheet; CMS Announces New Medicare App Library to Support Digital Health Tools; Study Finds Virtual Care Widely Used for Both Mental and Physical Health Needs.

Last week the Senate Committee on Health, Education, Labor & Pensions (HELP) released their report “Patients and Families First: Building the FDA of the Future.”  This report outlines legislative and regulatory reforms that will help update the Food and Drug Administration (FDA).  As noted in the report, advances in technology and medicine have improved or created ways in which to treat various health issues, but various regulatory barriers may impede or stall patient accessibility to these advancements. In particular, the report notes the potential of artificial intelligence (AI) to improve patient access and experience, but faces continued roadblocks to its more expansive use.

Interstate licensure compacts continue to gain momentum across the country. Many of the recent compacts have been developed with support from the Council of State Governments (CSG)’s National Center for Interstate Compacts (NCIC), which assists states in collaborating on complex public policy issues to strengthen economies, protect public health and safety, and preserve state sovereignty.  Beginning in 2021, the U.S. Department of War/Defense (DoD) partnered with CSG through a first-of-its-kind grant program to fund and support the development of occupational licensure compacts—particularly to address workforce challenges facing military spouses. This partnership has significantly accelerated compact development across professions.